Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Immutep
Biotech
Immutep regains pep as cancer subgroup data show path forward
Immutep has spotted a potential niche for its LAG3 drug candidate, reporting phase 2b data in a subset of head and neck cancer patients.
Nick Paul Taylor
Jul 12, 2024 9:35am
BMS CEO set to leave after 8-year run—Chutes & Ladders
Apr 28, 2023 9:30am
LAG-3-focused Immutep secures cash, plots new trial push
Jun 21, 2021 7:10am
SITC18: Merck highlights new LAG-3 and TIGIT data
Nov 7, 2018 11:05am
